Fundraising Fox6 Dimensions Capital — 2018 Investments
9 investments dated 2018 · listed companies and verified rows first · show all
GRAIL develops the Galleri blood test for multi-cancer early detection using next-generation sequencing and machine learning to screen for multiple deadly cancer types before symptoms appear.
AI & Machine LearningBiotechDigital HealthHealthtechMedical DevicesMenlo Park, US
Jeffrey T. Huber(Director)Joshua Ofman, MD, MSHS(Chief Executive Officer)inAaron Freidin(Executive Officer)inJosh Ofman(Executive Officer)inRobert Ragusa(Executive Officer, Director)Jennifer Cook(Executive Officer, Director)in
Co-investorsAmino CapitalARCH Venture PartnersBezos ExpeditionsBluebird VenturesDecheng CapitalDentsu Ventures+13 more
-2.png)
Kymera is a clinical-stage biotechnology company developing novel medicines using targeted protein degradation technology to treat diseases caused by previously "undrugged" proteins.
BiotechDeep TechHealthtech
Nello Mainolfi(Founder)inBruce Booth(Chair)in
Co-investorsAtlas VentureAvoro Capital AdvisorsBain Capital Life SciencesBessemer Venture PartnersHatteras Venture PartnersMRL Ventures Fund+6 more
Hong Kong-listed (2137.HK) biotech founded in 2018 developing infectious disease therapies, led by hepatitis B functional-cure programs.
Co-investorsARCH Venture PartnersBlue Pool CapitalBoyu CapitalSequoia Capital
Hong Kong-listed (HKEX: 2616) Chinese biopharmaceutical company developing oncology, immunology and inflammation therapies.
Co-investorsARCH Venture PartnersBoyu CapitalGICHillhouse CapitalWuXi Healthcare Ventures
Shanghai-based, HKEX-listed drug developer commercializing dorzagliatin, the first approved glucokinase activator for type 2 diabetes.
Co-investorsARCH Venture PartnersF-Prime CapitalVenrockAlly Bridge GroupBlue Pool CapitalEight Roads Ventures+2 more
Vizgen develops high-throughput spatial profiling technologies, including MERFISH-based spatial genomics and spatial proteomics tools for life science research and precision oncology.
AI & Machine LearningBiotechDeep TechHealthtechMedical DevicesCambridge, US
George Emanuel(Scientific Cofounder, VP & Portfolio Owner, Instruments)inJiang He(Scientific Cofounder, VP & Portfolio Owner, Reagents & Scientific Affairs)inXiaowei Zhuang(Founder; Professor, Harvard University)inFenel Eloi(Director)Rob Carson(Chief Executive Officer)inSimona Levi(Chief Legal Officer)in
Co-investorsARCH Venture PartnersNorthpond VenturesAlly Bridge GroupApplied VenturesKilonova CapitalPura Vida Investments+3 more
Unity Biotechnology was a biotechnology company that is no longer operating.
BiotechBrisbane, US
Nathaniel E. David(Executive Officer, Director)inDan Marquess(Executive Officer)inKeith Leonard(Executive Officer, Director)inTamara Tompkins(Executive Officer)inBob Goeltz(Executive Officer)inJamie Dananberg(Executive Officer)in
Co-investorsage1Alumni VenturesARCH Venture PartnersCycad Group LLCEcoR1 CapitalKhosla Ventures+6 more
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Erasca TxViela Bio
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.